Free Trial
NASDAQ:CASI

CASI Pharmaceuticals (CASI) Stock Price, News & Analysis

CASI Pharmaceuticals logo
$5.99
-0.13 (-2.12%)
(As of 10/31/2024 ET)

About CASI Pharmaceuticals Stock (NASDAQ:CASI)

Key Stats

Today's Range
$5.83
$6.20
50-Day Range
$5.27
$7.55
52-Week Range
$2.05
$8.48
Volume
26,014 shs
Average Volume
144,745 shs
Market Capitalization
$92.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
Consensus Rating
Buy

Company Overview

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

CASI Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
64th Percentile Overall Score

CASI MarketRank™: 

CASI Pharmaceuticals scored higher than 64% of companies evaluated by MarketBeat, and ranked 439th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CASI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    CASI Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about CASI Pharmaceuticals' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CASI Pharmaceuticals is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CASI Pharmaceuticals is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    CASI Pharmaceuticals has a P/B Ratio of 3.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about CASI Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    2.57% of the float of CASI Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    CASI Pharmaceuticals has a short interest ratio ("days to cover") of 4.1.
  • Change versus previous month

    Short interest in CASI Pharmaceuticals has recently decreased by 24.91%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    CASI Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    CASI Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.57% of the float of CASI Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    CASI Pharmaceuticals has a short interest ratio ("days to cover") of 4.1.
  • Change versus previous month

    Short interest in CASI Pharmaceuticals has recently decreased by 24.91%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    CASI Pharmaceuticals has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • Search Interest

    Only 1 people have searched for CASI on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added CASI Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CASI Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    21.24% of the stock of CASI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 22.23% of the stock of CASI Pharmaceuticals is held by institutions.

  • Read more about CASI Pharmaceuticals' insider trading history.
Receive CASI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CASI Stock News Headlines

Banking failure dead ahead
If you missed it, my emergency election broadcast is now available - but will be removed soon
BioInvent International AB (BIX0.DU)
CASI Pharmaceuticals, Inc. Q2 Loss Declines
Ligand Reports Second Quarter 2024 Financial Results
See More Headlines

CASI Stock Analysis - Frequently Asked Questions

CASI Pharmaceuticals' stock was trading at $7.16 at the beginning of 2024. Since then, CASI shares have decreased by 16.3% and is now trading at $5.99.
View the best growth stocks for 2024 here
.

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) issued its quarterly earnings results on Friday, August, 16th. The biotechnology company reported ($0.52) EPS for the quarter, topping analysts' consensus estimates of ($0.63) by $0.11. The biotechnology company earned $3.98 million during the quarter, compared to analyst estimates of $4.43 million. CASI Pharmaceuticals had a negative trailing twelve-month return on equity of 126.20% and a negative net margin of 118.81%.

Shares of CASI Pharmaceuticals reverse split before market open on Wednesday, June 1st 2022. The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that CASI Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Arista Networks (ANET), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

Last Earnings
8/16/2024
Today
10/31/2024
Next Earnings (Estimated)
11/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CASI
Employees
180
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$6.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+3.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-26,940,000.00
Net Margins
-118.81%
Pretax Margin
-120.57%

Debt

Sales & Book Value

Annual Sales
$23.10 million
Book Value
$1.81 per share

Miscellaneous

Free Float
12,177,000
Market Cap
$89.83 million
Optionable
Optionable
Beta
0.69

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (NASDAQ:CASI) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners